Phase II Study of Dostarlimab in Locally Advanced, Mismatch Repair–Deficient Rectal Cancer

June 3-7, 2022; Chicago, Illinois
Early data showed that among 14 patients with locally advanced, dMMR rectal cancer who completed treatment with the PD-1 inhibitor dostarlimab, all 14 achieved a clinical complete response, without the need for chemoradiotherapy or surgery.
Format: Microsoft PowerPoint (.ppt)
File Size: 122 KB
Released: June 14, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Related Content

Expert analysis module on key data from ESMO World GI 2022 in gastrointestinal cancers, from Clinical Care Options (CCO)

Joleen Hubbard, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 4, 2022 Expired: October 3, 2023

Phase I/II ReFocus: RLY-4008 in patients with FGFR inhibitor-naive cholangiocarcinoma with FGFR2 alterations, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Primary results from phase III LEAP-002 study of lenvatinib with or without pembrolizumab as first-line treatment for patients with advanced hepatocellular carcinoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings